Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amryt Pharma Plc ADR (NQ: AMYT )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 11, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amryt Pharma Plc ADR

< Previous 1 2 3 Next >
Amryt Reports Q3 2022 Financial and Operational Results
From Amryt Pharma plc
Via GlobeNewswire
Amryt Supports Acromegaly Awareness Day 2022
From Amryt Pharma plc
Via GlobeNewswire
The British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis Bullosa
From Amryt Pharma plc
Via GlobeNewswire
Amryt Supports Global EB Awareness Week 2022
From Amryt Pharma plc
Via GlobeNewswire
Filsuvez's European Approval Adds Growth Driver For Amryt Pharma
Via Benzinga
Recap: Amryt Pharma Q1 Earnings
Amryt Pharma (NASDAQ:AMYT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Amryt Shares Trading Higher As EMA Endorses Approval Of Filsuvez In Genetic Skin Disease
Via Benzinga
Amryt to Report Q3 2022 Results on November 3, 2022
From Amryt Pharma plc
Via GlobeNewswire
COMP adopts positive opinion on Orphan Disease Designation for Mycapssa® for the treatment of Acromegaly
From Amryt Pharma plc
Via GlobeNewswire
Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)
From Amryt Pharma plc
Via GlobeNewswire
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
Via Benzinga
Amryt Posts Long-Term Safety, Efficacy Mycapssa Data In Acromegaly Patients
Amryt Pharma Plc (NASDAQ: AMYT) has  
Via Benzinga
Recap: Amryt Pharma Q4 Earnings
Amryt Pharma (NASDAQ:AMYT) reported its Q4 earnings results on Wednesday, March 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Amryt Secures UK Regulatory Nod And Orphan Disease Status For Skin Disorder Candidate
The Medical Healthcare & Products Regulatory Agency (MHRA) has granted Marketing Authorisation Approval (MAA) and Orphan Disease Designation (ODD) for Amryt’s (NASDAQ: AMYT) lead candidate Filsuvez for... 
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
Amryt Shares Shoot Higher As FDA Grants Orphan Drug Status To Carcinoid Tumor Candidate
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Amryt’s (NASDAQ: AMYT) lead drug Mycapssa for the treatment of carcinoid syndrome. Carcinoid syndrome (CS) is the most... 
Via Benzinga
The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Amryt Pharma Plc (NASDAQ:AMYT) Shareholder Notice: Investigation Concerning Possible Wrongdoing
San Diego, CA -- (SBWIRE) -- 05/04/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Amryt Pharma plc. 
Via SBWire
Amryt Pharma Plc (NASDAQ:AMYT) Investor Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 03/21/2022 -- Amryt Pharma plc is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Amryt Pharma's Q4 FY21 Sales, FY22 Guidance Shy Of Street Consensus
Amryt Pharma Plc's (NASDAQ: AMYT) Q4 FY21 sales increased 29% Y/Y to $54.8 million, missing the consensus of $56.81 million. The growth was driven by metreleptin... 
Via Benzinga
55 Biggest Movers From Friday
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate... 
Via Benzinga
The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech On Humira Biosimilar Patent Dispute AbbVie, Inc... 
Via Benzinga
Earnings Scheduled For March 9, 2022
Companies Reporting Before The Bell • REV Group (NYSE:REVG) is expected to report quarterly earnings at $0.11 per share on revenue of $529.44 million. • Express (... 
Via Benzinga
A Preview Of Amryt Pharma's Earnings
Amryt Pharma (NASDAQ:AMYT) is set to give its latest quarterly earnings report on Wednesday, 2022-03-09. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
FDA Rejects Amryt Pharma's Oleogel-S10 Application For Skin Blistering Disorder
Amryt Pharma Plc (NASDAQ: AMYT) has received a Complete Response Letter (CRL) from the FDA regarding Oleogel-S10 application for cutaneous manifestations of... 
Via Benzinga
67 Biggest Movers From Yesterday
Gainers Mullen Automotive, Inc. (NASDAQ: MULN) climbed 145.6% to close at $1.69 on Monday after the company reported progress on solid-state polymer battery pack... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers IntriCon (NASDAQ:IIN) shares increased by 37.4% to $23.93 during Monday's regular session. The current volume of 1.0 million shares is 3684.0% of IntriCon'... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.